Publication Name	World Journal of Gastroenterology
Manuscript ID	35031
Country	Pakistan

Received	2017-07-11 20:58
Peer-Review Started	2017-07-12 01:39
First Decision by Editorial Office Director
Return for Revision	2017-08-10 06:51
Revised	2017-09-06 09:14
Publication Fee Transferred	2017-09-22 05:26
Second Decision by Editor	2017-09-08 02:07
Second Decision by Editor-in-Chief	2017-09-08 21:32
Final Decision by Editorial Office Director	2017-09-13 03:02
Articles in Press	2017-09-13 03:02
Edit the Manuscript by Language Editor	2017-11-08 23:39
Typeset the Manuscript	2017-11-17 02:33
Publish the Manuscript Online	2017-11-27 02:36

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Prospective Study
Article Title	Dramatic response of hepatitis C patients chronically infected with Hepatitis C virus genotype 3 to Sofosbuvir based therapies in Punjab, Pakistan: A prospective study
Manuscript Source	Unsolicited Manuscript
All Author List	Sajjad Iqbal, Muhammad Haroon Yousuf and Muhammad Iftikhar Yousaf
ORCID	Author(s) ORCID Number Sajjad Iqbal http://orcid.org/orcid.org/0000-0001-7476-7552 Muhammad Haroon Yousuf http://orcid.org/orcid.org/0000-0001-5448-0781 Muhammad Iftikhar Yousaf http://orcid.org/orcid.org/0000-0002-5099-9022
Funding Agency and Grant Number
Corresponding Author	Sajjad Iqbal, PhD, Doctor, Doctor, Pathology, Shalamar Hospital, Shalimar Link road Mughal Pura, Lahore 54840, Punjab, Pakistan. sajjad.iqbal@sihs.org.pk
Key Words	Sofosbuvir; Sustained virological response; Pakistan
Core Tip	Previously, Hepatitis C was treated with Interferon based therapies. Intolerable side effects, prolonged treatment duration, and unsatisfactory response rates were the major droughts of those therapies. The introduction of Sofosbuvir (SOF) that was claimed highly responding oral drug for Hapatitis C patients with its minimal side effects in different trials, it was important to see its efficacy in our population. We found outstanding response rate of SOF in HCV genotype 3 infected patients. These findings shows that with proper and timely use of SOF based therapy may help to get rid of Hepatitis C from our population.
Publish Date	2017-11-27 02:36
Citation	Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905
URL	http://www.wjgnet.com/1007-9327/full/v23/ i44/7899.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i44.7899

Full Article (PDF)	WJG-23-7899.pdf
Full Article (Word)	WJG-23-7899.doc